subcutaneous

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administrationEuropean Commission (EC) decision on…

Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatment…

CT-P13 SC is a novel subcutaneous formulation of infliximab The Biologics License Application (BLA) submission is based on phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC as maintenance therapy in patients…

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH) 1COMMODORE 3 is the first China-specific study in PNH. Current…